The approval is driven by Covid-19, as Bactiguard's endotracheal tubes can reduce the risk of secondary infections for critically ill patients
Health Canada has approved Bactiguard’s endotracheal tubes for infection prevention through an Interim Order.
The approval is driven by COVID-19, as Bactiguard’s endotracheal tubes can reduce the risk of secondary infections for critically ill patients.
“Many critically ill COVID-19 patients require intubation with an endotracheal tube (ETT) and mechanical ventilation. The ICU treatment period can be 14 days or more, which means patients will require ETTs for a long period of time. Each day of treatment increases the risk of acquiring ventilator acquired pneumonia, which is a very serious condition. The Canadian Patient Safety Institute estimates that VAP leads to 6-30 % additional deaths among critically ill patients and increases ICU length-of-stay with 8.7 days”, says Dr Stefan Grass, Chief Medical Officer and deputy CEO at Bactiguard.
“The global COVID-19 pandemic we now experience has highlighted the urgent need for infection prevention. The pressure on healthcare in general, and the ICUs in particular, is enormous. Therefore, we are very pleased to be able to offer ICU patients better protection against secondary infections in the form of endotracheal tubes from Bactiguard”, says Maik Rehfeldt, CEO of HANSAmed.
The Bactiguard coating technology for infection prevention reduces microbial adhesion to medical devices, which in turn reduces the risk of device-related infections. COVID-19 may lead to severe viral sepsis, with some patients suffering from multi organ failure.
The ICU treatment period is often 14 days or longer, and each day in hospital increases the risk for the patient of acquiring a device-related infection, such as ventilator-associated pneumonia (VAP). Bactiguard’s ETT has demonstrated a reduction of VAP of 38 % in a recent clinical trial.
Source: Company Press Release